Last updated 38 hours ago

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

1000 patients around the world

Available in Chile, United States, Mexico, Brazil

Hoffmann-La Roche

1000Patients around the world

Requirements for the patient

From 18 Years

All Gender

: Eligible for continuing atezolizumab-based therapy at the time of roll-over from the parent study, as per the parent study protocol or
Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
Time between the last dose of treatment received in parent study and first dose in extension study is no longer than the interruption period allowed in the parent study. First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of roll-over from the parent study as assessed by the investigator
Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential
For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs
For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

: Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
Study treatment or comparator agent is commercially marketed in the patient's country for the patient-specific disease and is accessible to the patient
Treatment with any anti-cancer treatment during the time between last treatment in the parent study and the first dose of study treatment in this extension study
Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
Ongoing serious adverse event(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study
Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications
Concurrent participation in any therapeutic clinical trial (other than the parent study)
Pregnant or lactating, or intending to become pregnant during this extension study and for the period after the last dose of study treatment specified in the designated referenced safety information (RSI)

StudyIMbrella B

SponsorHoffmann-La Roche

Study typeInterventional

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT03768063